Taureanbull I agree. The ASX has a stigma of being a biotech graveyard especially in a tougher market. I think management have done what they could to expand their horizons and opportunity by partnering with a US pharma and appointing Torreya for overseas scope and market prosperity.
Given that NEU basically just need to repeat the ph2 trials I'm confident we will get the tick for ph3 then regardless of the market manipulation the stock will see a truer value. IMO
GLTA - Patience is the call
Ann: Plans for Phase 3 trial in Rett syndrome, page-37
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.000(0.00%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.32 | $7.219M | 577.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2968 | $12.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 4 | 1 |
View Market Depth
| Last trade - 16.16pm 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |